Is the SH2B3 rs3184504 T allele associated with higher leukocyte, neutrophil, and monocyte traits and vascular risk?

The SH2B3 rs3184504 T allele represents a well-established genetic link between elevated hematopoietic activity, systemic inflammation, and cardiovascular disease.

Molecular and cellular mechanisms

• Loss of inhibitory control: The rs3184504 T allele is a missense variant (R262W) located in the pleckstrin homology domain of the Lnk/SH2B3 adaptor protein. It acts as a hypomorphic, partial loss-of-function mutation that impairs Lnk's capacity to negatively regulate JAK2/STAT and MPL signaling.
• Myeloid expansion and platelet aggregation: Unchecked signaling releases the physiological brake on hematopoietic stem cells, driving megakaryopoiesis and myelopoiesis. This results in elevated leukocytes, neutrophils, monocytes, and platelet counts, alongside the formation of highly prothrombotic platelet-leukocyte aggregates.
• T-cell hyperactivation: Altered Lnk function prevents the normal repression of the IL-12/STAT4 pathway, triggering excessive production of interferon-gamma (IFN-γ) by hyper-reactive T-cells.

Clinical and vascular risk

• Endothelial damage: Elevated IFN-γ promotes chronic endothelial activation, vascular remodeling, local tissue oxidative stress, and renal-vascular fibrosis.
• Atherosclerosis and thrombosis: Animal models of this variant demonstrate up to twofold increases in circulating myeloid lineages. In human populations, this persistent inflammatory state drives accelerated arterial plaque formation and thrombus stability, clinically translating to elevated risks for hypertension, coronary heart disease, and stroke.

Bottom line

• The SH2B3 rs3184504 T allele is a robustly supported driver of elevated myeloid traits and vascular risk. It acts by disabling Lnk's negative feedback loop, fostering a pro-inflammatory and prothrombotic environment that accelerates cardiovascular pathology.